Psychiatric NP Scope of Practice for General Psychiatry in Pennsylvania

If you’re a psychiatrist, PMHNP, or prescriber considering telehealth—or already running a virtual practice—you’ve probably asked yourself: ‘Can I legally prescribe Adderall, benzos, or buprenorphine over video without seeing the patient in person?’

The short answer in 2026: Yes, but the rules are changing. And if you don’t stay on top of federal DEA requirements and your state’s specific telehealth laws, you could find yourself out of compliance—or worse, dealing with a medical board investigation.

Let’s cut through the noise. This guide walks you through exactly what psychiatrists and psychiatric nurse practitioners need to know about prescribing controlled substances via telehealth right now, what’s coming down the pipeline, and how to stay compliant while building a thriving virtual practice.

The Current State of Play: Federal Telehealth Flexibilities Extended Through 2026

Here’s the reality: As of February 2026, you can still prescribe Schedule II–V controlled substances via telehealth to new patients without an initial in-person exam—but only because federal emergency flexibilities have been extended again.

On January 2, 2026, the DEA and HHS announced a fourth temporary extension of COVID-era telehealth prescribing rules through December 31, 2026. This means psychiatrists can continue prescribing stimulants for ADHD, benzodiazepines for anxiety, and other controlled medications after evaluating patients via two-way video, without disrupting care while permanent rules are being finalized.

What this means for your practice:

• You can evaluate a new patient via video (interactive audio-visual required—not just phone) and prescribe Schedule II medications like Adderall or Vyvanse for ADHD
• You can prescribe Schedule III–V medications (benzodiazepines, some sedatives, buprenorphine) after a proper telehealth evaluation
• If a patient was ever seen in person by you or another provider, there’s no federal restriction on prescribing controlled substances via follow-up telehealth visits
• Standard of care still applies: document your evaluation thoroughly, use clinical judgment, and check your state’s PDMP

The catch: This is a temporary extension. The DEA has proposed permanent rules that will change the landscape—likely sometime in late 2026 or 2027. More on that below.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: DEA’s Proposed Permanent Telemedicine Rules

The DEA isn’t planning to let the pandemic-era free-for-all continue indefinitely. In January 2025, they unveiled three proposed rules designed to balance access to care with patient safety. If you’re planning to build a long-term telehealth practice, you need to understand where things are headed.

1. Special Telemedicine Registration for Schedule II Prescribing

The DEA is creating a Special Telemedicine Prescriber Registration that will allow certain qualified providers to prescribe controlled substances to new patients via telehealth—no in-person exam required—if they obtain this special registration.

Here’s the key part for psychiatrists: Board-certified psychiatrists will be eligible to apply for this registration to prescribe Schedule II medications (stimulants, some opioids) via telehealth. The proposal also includes hospice/palliative care physicians, long-term care facility doctors, and pediatricians for limited uses.

For Schedule III–V substances, any qualified prescriber could get the registration. But for Schedule II—which includes the medications psychiatrists prescribe most often for ADHD—you’ll need to be a board-certified psychiatrist to qualify.

What this means: If finalized, this creates a clear legal pathway for telepsychiatrists to manage ADHD, narcolepsy, and other conditions requiring Schedule II stimulants entirely via telehealth. You’d register with the DEA, follow their protocols (likely including PDMP checks and documentation requirements), and maintain your ability to see patients remotely.

The trade-off: Online telehealth platforms will also have to register with the DEA for the first time, and the DEA plans to implement a national PDMP to track controlled prescriptions across state lines. Expect more administrative requirements—but also more legitimacy and clarity for virtual practices.

2. Buprenorphine for Opioid Use Disorder: 6-Month Telehealth Window

If you treat substance use disorders, this rule matters. The DEA proposes allowing clinicians to initiate and continue buprenorphine for opioid use disorder via telehealth (including audio-only) for up to 6 months before requiring an in-person evaluation.

After the initial 6-month period, patients would need at least one in-person visit to continue treatment. This is more permissive than the original Ryan Haight Act and reflects the reality that telemedicine has dramatically improved access to addiction treatment.

What this means for addiction psychiatrists: You can start patients on Suboxone or other buprenorphine formulations via video or even phone consultation (if video isn’t feasible), manage them for six months, and then ensure continuity with an in-person check. This recognizes that many patients in rural areas or underserved communities simply can’t access in-person addiction care.

3. Ryan Haight Act Still Applies (Mostly)

The Ryan Haight Act of 2008 is still the law of the land. It requires at least one in-person medical evaluation before prescribing controlled substances online, with specific exceptions.

Currently, those exceptions are suspended under the temporary federal extensions. But once the DEA’s permanent rules kick in, you’ll need to either:

• Have seen the patient in person at least once (by you or another provider in your practice), or
• Obtain the Special Telemedicine Registration (if eligible), or
• Limit prescribing to the specific carve-outs (like the 6-month buprenorphine window)

Bottom line: Don’t assume the current free pass will last forever. Plan for a future where some form of registration, in-person contact, or additional compliance steps will be required.

State Laws Matter Just as Much (Maybe More)

Federal DEA rules set the floor. State laws can—and do—impose stricter requirements. And because telehealth is considered to occur where the patient is located, you must comply with that state’s rules, even if you’re licensed and practicing from another state.

Let’s break down the key requirements in six major states where telehealth demand is high: California, Texas, Florida, New York, Pennsylvania, and Illinois.

California: Telehealth-Friendly, But PDMP Checks Are Mandatory

California doesn’t impose extra restrictions on controlled substance prescribing via telehealth beyond federal law. You can establish a patient relationship via video and prescribe as you would in person, as long as you meet the standard of care.

Key compliance requirements:

• PDMP (CURES) checks required before prescribing any Schedule II–IV controlled substance for the first time, and every 4 months if you continue prescribing
• 100% e-prescribing mandate (as of January 2022)—paper scripts are essentially banned
• Audio-only telehealth is allowed for follow-ups in some cases, but for initial controlled substance prescribing, use video

NP independence: California is transitioning to full practice authority for experienced NPs. As of 2024–2026, psychiatric NPs with 3+ years of supervised experience can practice independently (no collaborating physician required). This opens up opportunities for PMHNPs to join telehealth platforms without needing an MD on staff.

Texas: Strict NP Limits and Chronic Pain Restrictions

Texas allows telehealth prescribing under federal rules, but has some tough state-specific restrictions.

Key compliance requirements:

• PMHNPs and PAs cannot prescribe Schedule II medications outside of hospital or hospice settings—period. If you’re a psychiatric NP in Texas and a patient needs Adderall, a physician must write that prescription.
• Chronic pain prescribing via telehealth is prohibited unless the patient has had an in-person evaluation (this is more relevant for pain management than psychiatry, but be aware)
• PDMP (Texas PMP) checks mandatory before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol
• Real-time audio-video required for evaluations (no audio-only for initial prescribing)

What this means: If you’re a PMHNP, you’ll need a supervising physician or partner with a psychiatrist on your platform to handle stimulant prescriptions. If you’re a psychiatrist, you have full authority—just stay compliant with PDMP and documentation requirements.

Florida: Psychiatric Exception Saves the Day

Florida has one of the most restrictive telehealth controlled substance laws in the country—with a critical carve-out for psychiatry.

The rule: You cannot prescribe Schedule II controlled substances via telehealth in Florida unless it’s for:

1. Psychiatric disorder treatment
2. Inpatient hospital care
3. Hospice care
4. Nursing home resident care

What this means for psychiatrists: You’re good. Prescribing Adderall for ADHD or Vyvanse for binge eating disorder falls under ‘psychiatric disorder treatment.’ Just document the diagnosis clearly.

Other Florida quirks:

• Out-of-state providers can register as Florida telehealth providers without a full Florida license (unique among states), but the controlled substance limits still apply
• PDMP (E-FORCSE) checks required before prescribing any controlled substance to patients age 16+
• PMHNPs must have a collaborating physician (no independent practice for psychiatric NPs in Florida)

New York: PDMP Checks Required Every Time

New York is telehealth-friendly and allows video-based patient relationships without in-person exams. But the state has some of the strictest PDMP requirements in the country.

Key compliance requirements:

• Mandatory PMP check before prescribing every Schedule II, III, or IV controlled substance—not just the first time, but every time (this is the I-STOP law)
• 100% e-prescribing mandate (since 2016) for all prescriptions, controlled or not
• Audio-only allowed for mental health follow-ups, but initial controlled substance prescribing should be via video

NP independence: Experienced PMHNPs (3,600+ practice hours) can practice independently in New York without a collaborative agreement. This makes NY a great state for recruiting independent psychiatric NPs to telehealth platforms.

Pennsylvania: Follow Standard of Care, Check the PDMP

Pennsylvania doesn’t have a comprehensive telehealth statute yet, but the medical board allows telehealth prescribing as long as you meet the standard of care.

Key compliance requirements:

• PDMP checks required before prescribing opioids or benzodiazepines (and recommended for all controlled substances)
• E-prescribing required for Schedule II–V controlled substances (as of 2019)
• PMHNPs need a collaborative agreement with at least two physicians for prescriptive authority; they can prescribe Schedule II for up to 30 days, Schedule III–IV for up to 90 days

Bottom line: PA is less prescriptive (pun intended) than other states, but that means you need to document everything meticulously to show you’re following standard of care.

Illinois: Full Practice NPs, But Benzodiazepine Limits

Illinois allows full practice authority for experienced NPs, but with some quirks around controlled substances.

Key compliance requirements:

• PDMP (ILPMP) checks required each time before prescribing opioids (recommended for all controls)
• E-prescribing required for all controlled substances (as of January 2023)
• PMHNPs with Full Practice Authority (4,000+ hours, additional training) can prescribe independently—but must have a physician consultation relationship for benzodiazepines and Schedule II opioids, and can only prescribe 30-day supplies of those without consultation

What this means: An experienced PMHNP in Illinois can manage most psychiatric medications independently, but will need a consulting psychiatrist for ongoing benzo or stimulant prescriptions in certain cases.

Psychiatrist vs. PMHNP: Scope of Practice Differences

If you’re a psychiatrist (MD/DO), your scope of practice is straightforward: you have full independent authority to diagnose, treat, and prescribe all controlled substances in every state (subject to DEA and state telehealth rules). No supervision, no collaborative agreements—just licensure and compliance.

If you’re a psychiatric mental health nurse practitioner (PMHNP), your scope varies wildly by state:

• Full Practice States (NY, CA by 2026, some others): You can practice independently, prescribe controlled substances, and run your own telehealth practice without physician oversight (once you meet experience requirements)
• Reduced Practice States (PA, IL without FPA): You need a collaborative agreement with a physician, but can prescribe controlled substances under that agreement (with some limits)
• Restricted Practice States (TX, FL): You must have a supervising physician at all times, and face significant limits on what you can prescribe (e.g., no Schedule II in Texas outside hospitals)

For telehealth platforms: This means you need to structure your provider network differently depending on the state. In Texas, you’ll need MDs available to write stimulant prescriptions for NP patients. In New York or California, experienced NPs can handle everything independently.

The Economics of Telehealth: Why Platforms Like Klarity Make Sense

Let’s talk money. If you’re thinking, ‘I’ll just set up my own telehealth practice and market myself’—great. But be realistic about what that actually costs.

The DIY route:

• SEO takes 6–12 months of consistent investment before generating meaningful patient flow. Most solo psychiatrists don’t have the expertise or patience to rank on Google.
• Google Ads for mental health keywords cost $15–40+ per click, and most clicks don’t convert to booked patients. A realistic cost per booked patient through PPC is $200–400+.
• Directory listings (Psychology Today, Zocdoc) charge monthly fees ($100–300+) and you compete with hundreds of other providers on the same page. Zocdoc charges per booking ($35–100+), and when you factor in the monthly subscription, your total acquisition cost adds up fast.
• Agency/consultant fees, ad spend testing, staff time to handle and qualify leads, no-show rates from cold leads—when you add it all up, acquiring a qualified psychiatric patient through DIY marketing typically costs $200–500+ per patient, assuming you know what you’re doing.

Most providers don’t have $3,000–5,000/month to gamble on marketing channels with uncertain ROI.

The platform model (like Klarity Health):

• Pay-per-appointment model: You pay a standard listing fee per new patient lead. No upfront marketing spend, no monthly subscription fees.
• Pre-qualified patients already matched to your specialty and availability—no wasted ad spend on clicks that don’t convert.
• Built-in telehealth infrastructure: No separate platform costs for video, scheduling, EHR, or billing.
• Both insurance and cash-pay patient flow, depending on your preference.
• You control your schedule—only pay when you see patients.

The economic case: Instead of spending thousands per month on marketing with uncertain results, you pay only when a qualified patient books with you. That’s guaranteed ROI vs. gambling on SEO or Google Ads.

This is especially valuable if you’re starting out, scaling from part-time to full-time, or simply want to focus on clinical work instead of becoming a marketing expert.

Compliance Checklist: What Every Telepsychiatrist Should Do

Whether you’re on a platform or running your own practice, here’s your compliance baseline:

Federal (DEA) Requirements:

• ✅ Maintain an active DEA registration in each state where you treat patients
• ✅ Use real-time, two-way audio-visual communication for initial controlled substance evaluations (audio-only generally only permitted for buprenorphine OUD treatment under current rules)
• ✅ Complete the 8-hour MATE Act training on substance use disorder and pain management (required for all DEA registrations renewed after June 2023)
• ✅ Document evaluations thoroughly to show a legitimate patient-provider relationship and appropriate standard of care
• ✅ Stay updated on DEA’s final permanent telemedicine rules (expected late 2026/early 2027)

State Requirements (varies by state):

• ✅ Hold an active medical or nursing license in the state where the patient is located
• ✅ Check the state’s PDMP before prescribing controlled substances (mandatory in most states, especially for initial prescriptions and certain drug classes)
• ✅ Use e-prescribing for controlled substances (required in nearly all states, with few exceptions)
• ✅ Follow any state-specific telehealth prescribing restrictions (e.g., Florida’s psychiatric exception, Texas’s NP limitations)
• ✅ If you’re a PMHNP, ensure you have the required collaborative agreement or independent practice authority for your state

Clinical Best Practices:

• ✅ Obtain informed consent for telehealth from patients (document it)
• ✅ Provide patients with your credentials, license number, and how to file a complaint with the medical board (some states require this)
• ✅ Have a plan for emergencies (e.g., how to handle a suicidal patient over video)
• ✅ Use a HIPAA-compliant platform for video visits
• ✅ Review PDMP reports regularly, especially for patients on chronic benzodiazepines or stimulants
• ✅ Document any deviation from standard in-person care and your clinical reasoning

What Happens When the Rules Change?

The DEA’s proposed permanent rules are still in the comment period as of early 2026. Once finalized, here’s what to expect:

Best-case scenario (for providers):

• Special Telemedicine Registration becomes available for psychiatrists
• You register, pay a fee, meet reporting requirements, and continue prescribing Schedule II stimulants via telehealth indefinitely
• Buprenorphine rule creates a clear 6-month window for OUD treatment, then requires in-person follow-up

Likely scenario:

• DEA finalizes rules sometime in late 2026 or 2027
• Temporary extensions end (currently through December 31, 2026)
• Transition period where providers must either:
• Obtain the Special Registration
• See patients in person at least once (or ensure they’ve been seen by another provider)
• Limit certain prescriptions to conditions that qualify for carve-outs

What you should do now:

• Don’t panic. You have through the end of 2026 under current rules.
• Plan ahead. If you’re building a telehealth practice, assume you’ll need some form of additional registration or compliance step by 2027.
• Stay informed. Subscribe to DEA updates, join professional associations (APA, AANP), and watch for final rule announcements.
• Document everything. The better your clinical documentation, the more defensible your practice if rules tighten or if you’re ever audited.

FAQ: Top Questions Psychiatrists Ask About Telehealth Prescribing

Can I prescribe Adderall via telehealth to a new patient I’ve never met in person?
Yes, under current federal rules (extended through December 31, 2026), you can prescribe Schedule II stimulants like Adderall after evaluating a new patient via interactive audio-video telehealth. You must meet the standard of care, document the evaluation, and comply with state PDMP and e-prescribing requirements. Once permanent DEA rules take effect, you may need a Special Telemedicine Registration or an in-person exam.

What’s the difference between DEA rules and state telehealth laws?
DEA rules are federal and apply everywhere in the U.S.—they govern whether you can prescribe controlled substances via telehealth at all. State laws govern how you practice telehealth in that state (licensure, PDMP checks, e-prescribing, scope of practice for NPs, etc.). You must comply with both—and if state law is stricter, you follow the state law.

Do I need a separate DEA number for each state I practice in via telehealth?
Yes. If you’re treating patients in multiple states, you need a DEA registration for each state where you prescribe controlled substances. Each registration is tied to a practice location in that state (or you can use your home address if you’re a telehealth-only provider). Check with your state’s controlled substance authority for specifics.

Can PMHNPs prescribe controlled substances via telehealth independently?
It depends on the state. In full practice states like New York (after 3,600 hours) or California (by 2026 for experienced NPs), yes—PMHNPs can prescribe independently, including controlled substances. In restricted states like Texas or Florida, PMHNPs need a supervising physician and may face limits on Schedule II prescribing.

What happens if I prescribe controlled substances via telehealth and don’t check the PDMP?
You’re violating state law in most states, which can result in medical board discipline, fines, or even loss of license. PDMP checks are mandatory in nearly every state before prescribing opioids, benzodiazepines, or stimulants. Document every PDMP query in the patient’s chart.

Can I use audio-only (phone) for controlled substance prescribing?
Generally, no—not for initial evaluations or most controlled substances. The DEA’s current telehealth allowance requires interactive audio-visual communication (two-way video). The exception is buprenorphine for opioid use disorder, where audio-only has been permitted under certain circumstances. For Schedule II stimulants or benzodiazepines, use video.

What if a patient I’m treating via telehealth moves to another state?
You must either obtain a license (and DEA registration) in the new state, or refer the patient to a local provider. Telehealth is regulated based on where the patient is located, not where you are. There’s no ‘following your patient across state lines’ exception unless you’re licensed in both states.

How do I know if I need the Special Telemedicine Registration when it becomes available?
If you’re a board-certified psychiatrist and you want to continue prescribing Schedule II controlled substances to new patients via telehealth without an in-person exam, you’ll likely need it once the DEA’s permanent rule takes effect. The DEA will publish the application process and requirements. Stay tuned for updates in late 2026.

Ready to Build a Compliant, Profitable Telehealth Practice?

Telehealth prescribing for psychiatrists and PMHNPs in 2026 is legal, growing, and here to stay—but the rules are evolving. You have a clear window of opportunity through the end of 2026 under current federal flexibilities, and even after permanent DEA rules take effect, there will be pathways for compliant telepsychiatry (likely with some additional registration or documentation).

The key is staying ahead of the curve:

• Understand federal DEA requirements and your state’s specific laws
• Document thoroughly and use PDMP databases religiously
• If you’re a PMHNP, know your scope of practice limitations in each state you practice
• Plan for the future—assume some form of Special Registration or in-person contact will be required post-2026

And most importantly: Don’t try to build a telehealth practice alone unless you have deep pockets and a lot of time. Platforms like Klarity Health handle patient acquisition, compliance infrastructure, and scheduling so you can focus on what you do best—treating patients.

Interested in joining a telehealth platform that handles the marketing, credentialing, and compliance while you see patients on your schedule? Explore Klarity Health’s provider network and see if it’s the right fit for your practice.

References

1. U.S. Department of Health and Human Services. (January 2, 2026). HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026. Retrieved from https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration. (January 16, 2025). DEA Announces Three New Telemedicine Rules to Continue Open Access to Care. Retrieved from https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Substance Abuse and Mental Health Services Administration. (2023). MAT Act Waiver Elimination – Buprenorphine Prescribing. Retrieved from https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act

4. Florida Legislature. (2025). Florida Statutes §456.47 – Use of Telehealth to Provide Services. Retrieved from http://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

5. Akerman LLP. (March 2023). Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth. Retrieved from https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html

6. Texas Medical Board. (2024). Prescriptive Authority and Supervision FAQs. Retrieved from https://www.tmb.texas.gov/resources/for-applicants-and-licensees/prescribing-and-supervision

7. Tebra (The Intake). (December 4, 2025). Nurse Practitioner Scope of Practice Laws by State. Retrieved from https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state

8. Epstein Becker Green (JD Supra). (February 2023). States and Feds Signal Big Changes to Telehealth Prescribing. Retrieved from https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/

9. Texas Legislature. (88th Session, 2023). Senate Bill 2527 – Analysis (Telemedicine Controlled Substance Prescribing). Retrieved from https://capitol.texas.gov/tlodocs/88R/analysis/html/SB02527I.htm

10. California Medical Board. (2024). Newsletter Vol. 169 – New Laws and CURES PDMP Requirements. Retrieved from https://www.mbc.ca.gov/News/Newsletter/2024-Vol169.aspx

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices